Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation [3]

Journal of Investigative Dermatology

Volumn 125, Issue 6, 2005, Pages 1317-1319

  Rodriguez Burford, Cristina ^a   Tu, John H ^b,c   Mercurio, MaryGail ^b,c   Carey, Delicia ^a   Han, Rujing ^b,c   Gordon, Gary ^d   Niwas, Santosh ^a   Bell, Walter ^a   Elmets, Craig A ^a   Grizzle, William ^a   Pentland, Alice P ^b,c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Rochester ^*

^c PFIZER INC   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PLACEBO; CYCLINE; CYCLOOXYGENASE 2; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; ERYTHEMA; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN CANCER; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET IRRADIATION; METABOLISM; NOTE;

CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; ERYTHEMA; HUMANS; MEMBRANE PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRAZOLES; SULFONAMIDES;

EID: 33644815918     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23960.x     Document Type: Letter

References (24)

1. An KP, Athar M, Tang X, et al: Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: Implications for therapeutic approaches. Photochem Photobiol 76:73-80, 2002
2. Black HS, deGruijl FR, Forbes PD, et al: Photocarcinogenesis: An overview. J Photochem Photobiol B 40:29-47, 1997
3. Bruce AJ, Brodland DG: Overview of skin cancer detection and prevention for the primary care physician. Mayo Clin Proc 75:491-500, 2000
4. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP: COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis 19:723-729, 1998
5. Chulada PC, Thompson MB, Mahler JF, et al: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708, 2000
6. Dobrev H: Evaluation of the inhibitory activity of topical indomethacin, betamet-hasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity. Photodermatol Photoimmunol Photomed 17:184-188, 2001
7. Einspahr JG, Alberts DS, Warneke JA, et al: Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1:468-475, 1999
8. Farr PM, Diffey BL: A quantitative study of the effect of topical indomethacin on cutaneous erythema induced by UVB and UVC radiation. Br J Dermatol 115:453-466, 1986
9. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Cont CJ: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinogen 25:231-240, 1999
10. Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 124:869-871, 1988
11. Funk CD: Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294:1871-1875, 2001
12. Furstenberger G, Gross M, Marks F: Eicosanoids and multistage carcinogenesis in NMRI mouse skin: Role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis 10:91-96, 1989
13. Krontiras H, Roye GD, Beenken SE, Myers RB, Mayo MS, Peters GE, Grizzle WE: Fatty acid synthase expression is increased in neoplastic lesions of the oral tongue. Head Neck 21:325-329, 1999
14. Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE: Nuclear accumulation of p53 in colorectal adenocarcinoma: Prognostic importance differs with race and location of the tumor. Cancer 83:2456-2467, 1998
15. Marks F, Furstenberger G: Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. Eur J Cancer 36:314-329, 2000
16. Nakamura T, Kurimoto I, Itami S, Yoshikawa K, Streilein JW: Genetic factors in immunosuppression: Precise genetic evidence that polymorphism of TNF-alpha dictates UVB-susceptibility in mice. J Dermatol Sci 23 (Suppl. 1):S13-S16, 2000
17. Nickoloff BJ, Qin JZ, Chaturvedi V, Bacon P, Panella J, Denning MF: Life and death signaling pathways contributing to skin cancer. J Investig Dermatol Symp Proc 7:27-35, 2002
18. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R: Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20:1939-1944, 1999
19. Sales KJ, Katz AA, Davis M, et al: Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: A possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86:2243-2249, 2001
20. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN: Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62:424-432, 2002
21. Singh-Ranger G, Mokbel K: The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 28: 729-737, 2002
22. Tiano HF, Loftin CD, Akunda J, et al: Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395-3401, 2002
23. Urquhart J: Some key points emerging from the COX-2 controversy. Pharmacoepidemiol Drug Saf 14:145-147, 2005
24. Wilgus TA, Parrett ML, Ross MS, Tober KL, Robertson FM, Oberyszyn TM: Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Adv Exp Med Biol 507:85-92, 2002